Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy

Trial Profile

Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Olodaterol/tiotropium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms OTIVACTO
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 27 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 15 May 2017 Planned End Date changed from 23 Jan 2018 to 18 Jun 2018.
    • 15 May 2017 Planned primary completion date changed from 23 Jan 2018 to 18 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top